Zevra Therapeutics, Inc. (ZVRA) Stock

Zevra Therapeutics, Inc. (ZVRA) is a Healthcare stock trading at $9.53 (as of 2026-07-24), with a market capitalization of $563.37M and a trailing P/E of 5.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Zevra Therapeutics, Inc. develops prodrug therapeutics for rare diseases and other medical conditions using its Ligand Activated Therapy approach, including prodrug versions of FDA-approved medicines and other compounds for potential new indications. Its pipeline includes clinical-stage candidates KP1077 and KP879 for CNS and stimulant-related disorders, and it offers the approved ADHD medicine AZSTARYS in the U.S.

Understand Zevra Therapeutics, Inc.: how it makes money

Zevra Therapeutics develops proprietary prodrugs using its Ligand Activated Therapy technology, and it makes money from selling its prodrug products such as MyPlypha and from smaller milestone-related revenue.

The profit model appears to hinge on commercializing and scaling MyPlypha sales for near-term net revenue, while other prodrug programs show no current revenue and therefore are not yet contributing to earnings.

Revenue by segment (latest quarter)
MyPlypha$0.0B
Milestones$0.0B

Business quality (Exceptional): Near-term revenue visibility is limited, with MyPlypha accounting for most reported net revenue and reported revenue coming largely from a small set of lines.

Valuation: At 5× earnings, ZVRA trades 68% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • MyPlypha is generating reported net revenue (0.03B): This provides an observable commercial revenue base while other programs currently show 0.0B in the provided revenue lines.
  • Access and enrollment engagement metrics are tracked for MyPlypha: MyPlypha Covered Lives are reported at 38%, and MyPlypha Prescription Enrollment Forms Received are reported at 13.0.

Bear case

  • Revenue appears concentrated in one product and one additional line item: Provided revenue lines show MyPlypha revenue at 0.03B and Net Sales Milestone at 0.01B, with Olpruva, Elprova, Opruva, and royalty-related revenue lines at 0.0B.
  • Near-term performance depends on continuing enrollment and coverage progress: The company’s tracked MyPlypha operating metrics include Covered Lives and enrollment forms received, which could slow if formularies, coverage, or patient enrollment do not expand.
Valuation — source: SEC EDGAR (first-party)
Price$9.53
Market Cap$563.37M
P/E Ratio5.2
Price / Book2.74
Price / Sales5.19
FCF Yield-4.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$106.47M
Net Margin78.2%
Revenue Growth (YoY)350.9%
EPS Growth (YoY)-161.4%
FCF Growth (YoY)-96.5%
Financial Health — source: SEC EDGAR
Altman Z-Score0.92 (distress)
Valuation vs Sector & Industry
Stock P/E5.2
Sector P/E (Healthcare)21.2
Industry P/E (Pharmaceutical Products)17.0
vs Sector-75.6%
vs Industry-69.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($41.53M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEONeil F. McFarlane
Employees59
CountryUS
IPO Date2015-04-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • ARS Pharmaceuticals, Inc. (SPRY)
  • Gyre Therapeutics, Inc. (GYRE)
  • Shattuck Labs, Inc. (STTK)
  • Neurogene Inc. (NGNE)
  • Relmada Therapeutics, Inc. (RLMD)
  • Altimmune, Inc. (ALT)
  • Verastem, Inc. (VSTM)
  • Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
ZVRA earnings history · ZVRA institutional & insider holders · ZVRA KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.